Nuevos aspectos terapéuticos para el control de los factores de riesgo de la obesidad

Toumilehto, 2001, Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance, N Engl J Med, 344, 1343, 10.1056/NEJM200105033441801 Ross, 2000, Reduction in obesity and related comorbid conditions after diet-induced weight loss or exercise-induced weight loss in men. A randomized controlled trial, Ann Intern Med, 133, 92, 10.7326/0003-4819-133-2-200007180-00008 Paré, 2001, Is the relationship between adipose tissue and waist girth altered by weight loss in obese men?, Obes Res, 9, 526, 10.1038/oby.2001.69 2000 National Institutes of Health. National Heart, Lung and Blood Institute and the North American Association for the Study of Obesity. The practical guide. Identification, evaluation and treatment of overweight and obesity in adults. NIH Publication number 00-4084. October, 2000. Snow, 2005, Pharmacololgic and surgical management of obesity in primary care: a clinical practice guideline from the American College of Physicians, Ann Intern Med, 142, 525, 10.7326/0003-4819-142-7-200504050-00011 2000, Consenso SEEDO’ 2000 para la evaluación del sobrepeso y la obesidad y el establecimiento de criterios de intervención terapéutica, Med Clin (Barc), 115, 587, 10.1016/S0025-7753(00)71632-0 Hansen, 1999, The effect of sibutramine on energy expenditure and apptetite during chronic treatment without dietary restriction, Int J Obes Relat Metab Disord, 23, 1016, 10.1038/sj.ijo.0801059 Astrup, 2001, When, for whom and how to use sibutramine?, Int J Obes Relat Metab Disord, 25, 2, 10.1038/sj.ijo.0801930 James, 2000, Effect of sibutramine on weight maintenance after weight loss: a randomized trial. STORM Study Group. Sibutramine trial on obesity reduction and maintenance, Lancet, 356, 2119, 10.1016/S0140-6736(00)03491-7 Sharma, 2001, Sibutramine in overweight/obese hypertensive patients, In J Obes Relat Metab Disord, 25, 20, 10.1038/sj.ijo.0801934 Yee, 2006, The effect of sibutramine-assisted weight loss in men with obstructive sleep apnoea, Int J Obes Sjöstrom, 1998, Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients, Lancet, 352, 167, 10.1016/S0140-6736(97)11509-4 Rössner, 2000, Weight loss, weight maintenance and improved cardiovascular risk factors after two years of treatment with orlistat for obesity, Obes Res, 8, 49, 10.1038/oby.2000.8 Muls, 2001, The effects of orlistat on weight and serum lipids in obese patients with hypercolesterolemia: a randomized, double-blind, placebo-controlled, multicentre study, In J Obes Relat Metab Disord, 25, 1713, 10.1038/sj.ijo.0801814 Torgerson, 2004, Xenical in the prevention of diabetes in obese subjects (XENDOS) study, Diabetes Care, 27, 155, 10.2337/diacare.27.1.155 Toplak, 2005, XPERT: weight reduction with orlistat in obese subjects receiving a mildly or moderately reduced-energy diet: early response to treatment predicts weight maintenance, Diabetes Obes Metab, 7, 699, 10.1111/j.1463-1326.2005.00483.x Hauptman, 2000, Orlistat in the long-term treatment of obesity in primary care settings, Arch Fam Med, 9, 160, 10.1001/archfami.9.2.160 Lobstein, 2003, Prevalence of overwight among children in Europe, Obes Rev, 4, 195, 10.1046/j.1467-789X.2003.00116.x Arslanian, 2002, Type 2 diabetes in children: clinical aspects and risk factors, Horm Res, 57, 19, 10.1159/000053308 Cook, 2003, Prevalence of a metabolic syndrome phenotype in adolescents: findings from the third NHANES, 1988-94, Arch Pediatr Adolesc Med, 157, 821, 10.1001/archpedi.157.8.821 Young, 2002, Epidemiololgy of obstructive sleep apnea: a population health perspective, Am J Respir Crit Care Med, 165, 1217, 10.1164/rccm.2109080 Reisler, 2006, Sibutramine as an adjuvant therapy in adolescents suffering from morbid obesity, Isr Med Assoc J, 8, 30 Chanoine, 2005, Effect of orlistat on weight and body composition in obese adolescents, JAMA, 293, 2873, 10.1001/jama.293.23.2873 Pagotto, 2005, Fighting obesity and associated risk factors by antagonising cannabinoid type 1 receptors, Lancet, 365, 1363, 10.1016/S0140-6736(05)66348-9 Rinaldi-Carmona, 1994, SR141716A, a potent and selective antagonist of the brain cannabinoid receptor, FEBS Lett, 350, 240, 10.1016/0014-5793(94)00773-X Di Marzo, 2001, Leptinregulated endocannabinoids are involved in maintaining food intake, Nature, 410, 822, 10.1038/35071088 Després, 2005, Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia, N Engl J Med, 353, 2121, 10.1056/NEJMoa044537 Van Gaal, 2005, Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study, Lancet, 365, 1389, 10.1016/S0140-6736(05)66374-X Pi-Sunyer, 2006, Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients, JAMA, 295, 761, 10.1001/jama.295.7.761